Literature DB >> 7620119

Spinocerebellar ataxia type 1.

H Y Zoghbi1, H T Orr.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disorder characterized by ataxia, dysarthria and progressive bulbar dysfunction. The SCA 1 gene which maps to the short arm of chromosome 6 has been isolated using a positional cloning approach. The SCA1 transcript is 10660 bases and encodes a novel protein, ataxin-1, with a predicted molecular weight of 87 kDa. Expansion of a CAG repeat localized near the amino terminus of ataxin-1 has been found to be the mutational mechanism in SCA1. This CAG repeat is highly polymorphic with normal alleles containing 6-39 repeats. Individuals affected with SCA1 have one normal allele and one expanded allele containing 40-81 repeats. The size of the repeat correlates inversely with the age of onset of symptoms and the severity of disease. The repeat is a continuous CAG repeat tract on SCA1 chromosomes whereas in > or = 98% of normal alleles one or more CAT interruptions break the CAG repeat tracts into two tracts containing less than 18 repeats each. This suggests that loss of CAT interruptions within the SCA1 CAG repeat on normal chromosomes leads to triplet instability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620119     DOI: 10.1016/1043-4682(95)90012-8

Source DB:  PubMed          Journal:  Semin Cell Biol        ISSN: 1043-4682


  35 in total

Review 1.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

Review 2.  The genetic defect causing Huntington's disease: repeated in other contexts?

Authors:  J F Gusella; F Persichetti; M E MacDonald
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 3.  Recent advances in RNA interference therapeutics for CNS diseases.

Authors:  Pavitra S Ramachandran; Megan S Keiser; Beverly L Davidson
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

4.  Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Ryan L Boudreau; Beverly L Davidson
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

5.  Cellular fusion for gene delivery to SCA1 affected Purkinje neurons.

Authors:  K Amy Chen; Pedro E Cruz; Derek J Lanuto; Terence R Flotte; David R Borchelt; Arun Srivastava; Jianyi Zhang; Dennis A Steindler; Tong Zheng
Journal:  Mol Cell Neurosci       Date:  2011-03-17       Impact factor: 4.314

6.  Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.

Authors:  Nupur Nag; Volga Tarlac; Elsdon Storey
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

7.  Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1.

Authors:  Gülin Oz; Christopher D Nelson; Dee M Koski; Pierre-Gilles Henry; Malgorzata Marjanska; Dinesh K Deelchand; Ryan Shanley; Lynn E Eberly; Harry T Orr; H Brent Clark
Journal:  J Neurosci       Date:  2010-03-10       Impact factor: 6.167

Review 8.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

9.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

10.  Assignment of the 1H, 13C, and 15N resonances of the AXH domain of the transcription factor HBP1.

Authors:  Cesira de Chiara; Geoff Kelly; Thomas A Frenkiel; Annalisa Pastore
Journal:  J Biomol NMR       Date:  2004-04       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.